Search results
Results from the WOW.Com Content Network
Later the cryo-EM structure of telomerase was first reported in T. thermophila, to be followed a few years later by the cryo-EM structure of telomerase in humans. [8] The role of telomeres and telomerase in cell aging and cancer was established by scientists at biotechnology company Geron with the cloning of the RNA and catalytic components of ...
Telomeres at the end of a chromosome. The relationship between telomeres and longevity and changing the length of telomeres is one of the new fields of research on increasing human lifespan and even human immortality. [1] [2] Telomeres are sequences at the ends of chromosomes that shorten with each cell division and determine the lifespan of ...
The cloning of the catalytic component of telomerase enabled experiments to test whether the expression of telomerase at levels sufficient to prevent telomere shortening was capable of immortalizing human cells. Telomerase was demonstrated in a 1998 publication in Science to be capable of extending cell lifespan, and now is well-recognized as ...
Telomerase reverse transcriptase (abbreviated to TERT, or hTERT in humans) is a catalytic subunit of the enzyme telomerase, which, together with the telomerase RNA component (TERC), comprises the most important unit of the telomerase complex. [5] [6] Telomerases are part of a distinct subgroup of RNA-dependent polymerases.
Telomerase is the ribonucleoprotein responsible for adding species-dependent tandem repeat sequences (TTAGGG in humans) to the ends of telomeres. These telomeric repeats function to protect the ends of the chromosome from DNA damage or end-to-end fusion with adjacent chromosomes.
Their longevity may be due to telomerase, an enzyme that repairs long repetitive sections of DNA sequences at the ends of chromosomes, referred to as telomeres. Telomerase is expressed by most vertebrates during embryonic stages but is generally absent from adult stages of life. [ 25 ]
Two concerns with applying telomerase inhibitors in cancer treatment are that effective treatment requires continuous, long-term drug application and that off-target effects are common. [30] For example, the telomerase inhibitor imetelstat, first proposed in 2003, [31] [32] has been held up in clinical trials due to hematological toxicity. [30]
Telomere-binding proteins function to generate a T-loop, which is a specialized loop structure to cap the telomeric ends. Telomerase activity is regulated by protection of telomeres 1 (POT1). [9] They serve as a protective safeguard against premature degradation as the telomere ends are no longer hidden from damage detection.